Celldex Therapeutics Completes Acquisition of CuraGen Corporation for $93.5 Million

Celldex Therapeutics Completes Acquisition of CuraGen Corporation for $93.5 Million

Client News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
On October 1, Celldex Therapeutics, Inc. announced the successful completion of its acquisition of CuraGen Corporation. The purchase price for CuraGen was approximately $93.5 million and, as a result of the merger, CuraGen has become a wholly owned subsidiary of Celldex. The acquisition adds a portfolio of oncology-focused, fully-owned antibodies to Celldex's Precision Targeted Immunotherapy Platform.

WilmerHale represented CuraGen in this transaction. The WilmerHale team included Lara Mataac and Ravi Faiia from the Corporate Group, and Kimberly Wethly from the Tax Group. William Schmidt advised on employee benefits, Sally Byrne advised on licensing and Michael Twomey advised on patent matters.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel